{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Intestine+Adenocarcinoma&page=2",
    "query": {
      "condition": "Small Intestine Adenocarcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Intestine+Adenocarcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:10:27.175Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04981119",
      "title": "Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Solid Tumor, Adult",
        "Colorectal Cancer",
        "Non Small Cell Lung Cancer",
        "Pancreatic Cancer",
        "CRC",
        "NSCLC",
        "Pancreas Cancer",
        "Mesothelioma",
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Ovarian Carcinoma",
        "Mesothelioma, Malignant",
        "Mesothelioma; Lung",
        "Cancer",
        "Triple Negative Breast Cancer (TNBC)",
        "Renal Cell Carcinoma (Kidney Cancer)",
        "Head and Neck Squamous Cell Carcinoma HNSCC"
      ],
      "interventions": [
        {
          "name": "Apheresis",
          "type": "OTHER"
        },
        {
          "name": "Next Generation Sequencing (NGS)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Long Range NGS HLA typing",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2021-10-29",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-05-22T03:10:27.175Z",
      "location_count": 16,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04981119"
    },
    {
      "nct_id": "NCT07124000",
      "title": "DESTINY-PANTUMOUR04",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenocarcinoma (NOS)",
        "Anal Cancer",
        "Bladder Cancer",
        "Cervical Cancer",
        "Endometrial Cancer",
        "Esophageal Cancer",
        "Gall Bladder Cancer",
        "Gastrointestinal Stromal Tumour",
        "Head and Neck Cancer",
        "Liver Cancer",
        "Melanoma",
        "Mouth Cancer",
        "Nasopharangeal Cancer",
        "Neuroendocrine, Gastrointestinal Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer",
        "Renal Cell Carcinoma",
        "Salivary Gland Cancer",
        "Sarcoma",
        "Small Cell Lung Cancer",
        "Testicular Cancer",
        "Throat Cancer",
        "Thyroid Cancer",
        "Urethral Cancer",
        "Vaginal Cancer",
        "Vulvar Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-09-18",
      "completion_date": "2028-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-05-22T03:10:27.175Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bullhead City",
          "state": "Arizona"
        },
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07124000"
    },
    {
      "nct_id": "NCT07169734",
      "title": "A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cervical Squamous Cell Carcinoma",
        "Squamous Non-small-cell Lung Cancer",
        "Colorectal Cancer",
        "Intrahepatic Cholangiocarcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "ALE.P03",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alentis Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2025-08-26",
      "completion_date": "2029-10-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-05-22T03:10:27.175Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07169734"
    },
    {
      "nct_id": "NCT05563272",
      "title": "89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Glioblastoma Multiforme",
        "Cholangiocarcinoma",
        "Hepatocellular Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Nasopharyngeal Carcinoma",
        "Non Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Epithelial Ovarian Cancer",
        "Pancreatic Ductal Adenocarcinoma",
        "Soft Tissue Sarcoma",
        "Gastric Adenocarcinoma",
        "Malignant Mesothelioma (MM)",
        "Von Hippel Lindau",
        "Bladder Cancer",
        "Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "89Zr-girentuximab for PET/CT imaging of CAIX positive tumors",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Telix Pharmaceuticals (Innovations) Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 11,
      "start_date": "2023-06-06",
      "completion_date": "2025-05-09",
      "has_results": false,
      "last_update_posted_date": "2025-07-10",
      "last_synced_at": "2026-05-22T03:10:27.175Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Traverse City",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05563272"
    },
    {
      "nct_id": "NCT05958199",
      "title": "A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "NPX267",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NextPoint Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2023-07-21",
      "completion_date": "2025-09-20",
      "has_results": false,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-05-22T03:10:27.175Z",
      "location_count": 7,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 4 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05958199"
    },
    {
      "nct_id": "NCT03794128",
      "title": "A Study of Personalized Neoantigen Cancer Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Colorectal Cancer",
        "Gastroesophageal Adenocarcinoma",
        "Urothelial Carcinoma",
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Blood collection for research (next-generation sequencing [NGS])",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood collection for research (HLA typing)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Gritstone bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2018-07-25",
      "completion_date": "2020-05-26",
      "has_results": false,
      "last_update_posted_date": "2020-09-11",
      "last_synced_at": "2026-05-22T03:10:27.175Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • New York, New York • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03794128"
    },
    {
      "nct_id": "NCT04985604",
      "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Solid Tumor",
        "CRAF Gene Amplification",
        "RAF1 Gene Amplification",
        "BRAF Gene Fusion",
        "BRAF Fusion",
        "CRAF Gene Fusion",
        "CRAF Fusion",
        "RAF1 Gene Fusion",
        "RAF1 Fusion",
        "Thyroid Cancer, Papillary",
        "Spitzoid Melanoma",
        "Pilocytic Astrocytoma",
        "Pilocytic Astrocytoma, Adult",
        "Non Small Cell Lung Cancer",
        "Non-Small Cell Adenocarcinoma",
        "Colorectal Cancer",
        "Pancreatic Acinar Carcinoma",
        "Spitzoid Malignant Melanoma",
        "Bladder Cancer",
        "Bladder Urothelial Carcinoma",
        "MAP Kinase Family Gene Mutation",
        "RAF Mutation"
      ],
      "interventions": [
        {
          "name": "Tovorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Day One Biopharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2021-07-15",
      "completion_date": "2024-07-08",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-05-22T03:10:27.175Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04985604"
    },
    {
      "nct_id": "NCT07145255",
      "title": "Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Castration-resistant Prostate Cancer",
        "Breast Cancer",
        "Colo-rectal Cancer",
        "Lung Cancer (Non-Small Cell)",
        "Pancreas Cancer, Duct Cell Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "ADC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MBrace Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-09-03",
      "completion_date": "2029-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-05-22T03:10:27.175Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Irving",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07145255"
    },
    {
      "nct_id": "NCT04244552",
      "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Non-Small Cell Lung Cancer",
        "Acral Lentiginous Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "DMMR Colorectal Cancer",
        "MSI-H Colorectal Cancer",
        "Melanoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ATRC-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Atreca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2020-02-11",
      "completion_date": "2023-11-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-05-22T03:10:27.175Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04244552"
    },
    {
      "nct_id": "NCT00096083",
      "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "isolated perfusion",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Delcath Systems Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2004-09",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2013-10-23",
      "last_synced_at": "2026-05-22T03:10:27.175Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096083"
    }
  ]
}